The investment objective is to provide above average capital growth over the medium to long term from a diverse portfolio of US securities in any economic sector.
Name | % Net Assets |
---|---|
Citigroup | 4.7% |
Microsoft | 3.8% |
Morgan Stanley | 3.3% |
Wyeth | 3.0% |
Wells Fargo | 3.0% |
UnitedHealth | 3.0% |
Sprint Nextel | 3.0% |
American International | 2.7% |
Exelon | 2.6% |
Genzyme | 2.6% |
Key | % Net Assets |
---|---|
Citigroup | 4.7% |
Microsoft | 3.8% |
Morgan Stanley | 3.3% |
Wyeth | 3.0% |
Other | 85.2% |
Date | 21-Nov-2024 |
---|---|
NAV | 549.60p |
Currency | GBP |
Change | 4.30p |
% | 0.79% |
YTD change | 111.30p |
YTD % | 25.39% |
Fund Inception | 19/02/2001 |
---|---|
Fund Manager | Maximillian Anderl |
TER | - |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | £500 |
Savings | £50 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research